283 related articles for article (PubMed ID: 14973304)
1. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity.
Shadle CR; Lee Y; Majumdar AK; Petty KJ; Gargano C; Bradstreet TE; Evans JK; Blum RA
J Clin Pharmacol; 2004 Mar; 44(3):215-23. PubMed ID: 14973304
[TBL] [Abstract][Full Text] [Related]
2. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe.
Majumdar AK; McCrea JB; Panebianco DL; Hesney M; Dru J; Constanzer M; Goldberg MR; Murphy G; Gottesdiener KM; Lines CR; Petty KJ; Blum RA
Clin Pharmacol Ther; 2003 Aug; 74(2):150-6. PubMed ID: 12891225
[TBL] [Abstract][Full Text] [Related]
3. Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant.
Stoch SA; Gargano C; Valentine J; Braun MP; Murphy MG; Fedgchin M; Majumdar A; Pequignot E; Gottesdiener KM; Petty KJ; Panebianco D; Dean D; Kraft WK; Greenberg HE
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1313-21. PubMed ID: 20734049
[TBL] [Abstract][Full Text] [Related]
4. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin.
Depré M; Van Hecken A; Oeyen M; De Lepeleire I; Laethem T; Rothenberg P; Petty KJ; Majumdar A; Crumley T; Panebianco D; Bergman A; de Hoon JN
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):341-6. PubMed ID: 15983826
[TBL] [Abstract][Full Text] [Related]
5. Effect of aprepitant on the pharmacokinetics of intravenous midazolam.
Majumdar AK; Yan KX; Selverian DV; Barlas S; Constanzer M; Dru J; McCrea JB; Ahmed T; Frick GS; Kraft WK; Petty KJ; Greenberg HE
J Clin Pharmacol; 2007 Jun; 47(6):744-50. PubMed ID: 17463213
[TBL] [Abstract][Full Text] [Related]
6. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting.
Dando TM; Perry CM
Drugs; 2004; 64(7):777-94. PubMed ID: 15025555
[TBL] [Abstract][Full Text] [Related]
7. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
Darwish M; Kirby M; Robertson P; Hellriegel ET
Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects.
Marbury TC; Ngo PL; Shadle CR; Jin B; Panebianco D; Caro L; Valentine J; Murphy G
J Clin Pharmacol; 2011 Dec; 51(12):1712-20. PubMed ID: 21209230
[TBL] [Abstract][Full Text] [Related]
9. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD
Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
[TBL] [Abstract][Full Text] [Related]
10. Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects.
Wang J; Zhang ZY; Lu S; Powers D; Kansra V; Wang X
Support Care Cancer; 2019 Mar; 27(3):819-827. PubMed ID: 30084103
[TBL] [Abstract][Full Text] [Related]
11. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
[TBL] [Abstract][Full Text] [Related]
12. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
de Jonge ME; Huitema AD; Holtkamp MJ; van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2005 Oct; 56(4):370-8. PubMed ID: 15838656
[TBL] [Abstract][Full Text] [Related]
13. Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.
Hsyu PH; Pignataro DS; Matschke K
Eur J Clin Pharmacol; 2017 Jan; 73(1):49-56. PubMed ID: 27718000
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant.
Sanchez RI; Wang RW; Newton DJ; Bakhtiar R; Lu P; Chiu SH; Evans DC; Huskey SE
Drug Metab Dispos; 2004 Nov; 32(11):1287-92. PubMed ID: 15304427
[TBL] [Abstract][Full Text] [Related]
15. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
Loos WJ; de Wit R; Freedman SJ; Van Dyck K; Gambale JJ; Li S; Murphy GM; van Noort C; de Bruijn P; Verweij J
Cancer Chemother Pharmacol; 2007 Feb; 59(3):407-12. PubMed ID: 17051369
[TBL] [Abstract][Full Text] [Related]
16. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.
Bakhshi S; Batra A; Biswas B; Dhawan D; Paul R; Sreenivas V
Support Care Cancer; 2015 Nov; 23(11):3229-37. PubMed ID: 25851802
[TBL] [Abstract][Full Text] [Related]
17. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
18. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis.
Jenkins J; Williams D; Deng Y; Collins DA; Kitchen VS
Eur J Clin Pharmacol; 2010 Jan; 66(1):67-76. PubMed ID: 19756558
[TBL] [Abstract][Full Text] [Related]
19. Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial.
Krösser S; Neugebauer R; Dolgos H; Fluck M; Rost KL; Kovar A
Eur J Clin Pharmacol; 2006 Apr; 62(4):277-84. PubMed ID: 16525816
[TBL] [Abstract][Full Text] [Related]
20. The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients.
Walko CM; Combest AJ; Spasojevic I; Yu AY; Bhushan S; Hull JH; Hoskins J; Armstrong D; Carey L; Collicio F; Dees EC
Cancer Chemother Pharmacol; 2012 May; 69(5):1189-96. PubMed ID: 22245954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]